Myopia and Presbyopia Treatment Market - Growth Drivers and Challenges
Growth Drivers
-
Government expenditure on vision correction: The U.S. Medicare is the largest payer for eye disease treatments, paying for 41% of beneficiaries with AMD, cataract, DR, and glaucoma claims. Overall, Medicare spent $10.2 billion on vision-related diseases. These vision-related diseases account for 4% of Medicare Part B and 1% of Part D expenditures, with treatment costs per individual averaging between $360 for cataract and $1,290 for AMD annually, as stated in the CDC May 2024 report.
-
Personal out-of-pocket expenditure on vision care: Nearly USD 4993 is spent annually by every citizen in the U.S. including vision correction stated by NLM report in March 2024. Further, the total financial burden on visual disorder stated in the CDC May 2024 report is $35.4 billion. This expense is covered for both surgical and drug-based treatments for presbyopia and myopia. Despite the challenges in insurance coverage the demand is supported by lifestyle requirements and convenience considerations, which indicate a sustained transition toward self-funded refractive care.
-
Cost-effectiveness of vitamin therapy in AMD management: As per the CDC report in May 2024, the age-related macular degeneration has shown that vitamin therapy such as prophylactic antioxidant vitamins combined with zinc reduces the progression and incidence of AMD. The therapy has minimized the proportion of early AMD patients developing visual impairment for better vision result from 7.0% to 5.6%. while comparing with other treatments, vitamin therapy is more effective in lowering the vision loss and managing AMD and preserving the patient eye sight.
Survey Report on the Prevalence and Trends of Myopia Challenge
|
Parameter |
Study 1 (2022) |
Study 2 (2023) |
|
Participants |
1,285,609 |
1,059,838 eligible; 1,013,206 included (95.6% participation) |
|
Age (years) |
Mean: 11.80 ± 3.07 (range 6-20) |
Mean: 11.57 ± 3.36 (range 5-20) |
|
Gender |
658,516 males (51.2%) |
Male-to-female ratio: 1.11 |
|
High Myopia Prevalence |
2019: 4.48% |
Overall: 1.12% (elementary) |
|
Total Myopia Prevalence |
- |
Whole city-level: 75.35% |
|
Low Myopia Prevalence |
- |
Elementary: 48.56% |
|
Trend Observed |
Prevalence increased with age (11-17 yrs); higher in coastal/southern cities (2.60-5.83%). Rates decreased across all school stages from 2019-2021 |
Prevalence increased with age and grade. Fastest increase at ages 7-9. SE decreased with age/grade |
|
Predictive Factors |
Age, uncorrected distance VA, spherical equivalents |
Age, grade, SE. |
|
Model Performance |
Random forest: Accuracy 0.948, AUC 0.975 |
- |
Source: Frontiers, July 2022, JMIR, March 2023
Historical Data on the Prevalence of Myopia Cases
|
Year |
Affected Population (Billions) |
Prevalence % |
|
2000 |
1.4 |
22.9% |
|
2010 |
2.0 |
28.3% |
|
2020 |
2.6 |
33.9% |
|
2024 |
2.2 |
36% |
Source: WHO, August 2023, THE INTERNATIONAL MYOPIA INSTITUTE 2025
Challenges
-
Government pricing caps: In 2023, nations such as France and Germany imposed strict price caps on eye care treatments under their public health plans, limiting reimbursement levels for pharmacologic therapies like pilocarpine-based eye drops. This dramatically lowered commercial profitability for companies. For example, a company reacted by winning a tiered pricing agreement with French health authorities, securing wider market penetration and boosting the sales. These cost controls through regulation remain to hinder revenue growth in Western Europe.
Myopia and Presbyopia Treatment Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.4% |
|
Base Year Market Size (2025) |
USD 27.7 billion |
|
Forecast Year Market Size (2035) |
USD 46.8 billion |
|
Regional Scope |
|
